News | July 01, 2009

Study Evaluates Safety, Tolerability of Drug for Acute Decompensated Heart Failure

July 1, 2009 – Cardioxyl Pharmaceuticals Inc. announced today the initiation of a phase I/IIa dose-escalation study of lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure (ADHF).

The study has already begun enrollment, and researchers dosed the first patient in June 2009. The study will evaluate the safety and tolerability of CXL-1020 and its specific effects on noninvasive hemodynamic parameters in patients with chronic stable heart failure. It will also evaluate the pharmacokinetics of CXL-1020.

The company hopes the drug will provide a safe and effective therapy to enhance both diastolic and systolic function while concomitantly reducing vascular resistance. CXL-1020 is a novel, first-in-class, small molecule nitroxyl (HNO) donor therapeutic drug candidate.

“In preclinical trials, CXL-1020 has exhibited a very attractive suite of physiologic effects in canine models of heart failure,” said Wilson S. Colucci, M.D., Boston University Medical Center Cardiovascular Center and Steering Committee chair. “We look forward to evaluating the safety and tolerability, as well as the hemodynamic effects of CXL-1020 in this dose-escalation study.”

For more information:

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init